Article citationsMore>>

Bea, A.M., Perez-Calahorra, S., Marco-Benedi, V., Lamiquiz-Moneo, I., Jarauta, E., Mateo-Gallego, R., et al. (2017) Effect of Intensive LDL Cholesterol Lowering with PCSK9 Monoclonal Antibodies on Tendon Xanthoma Regression in Familial Hypercholesterolemia. Atherosclerosis, 263, 92-96.
https://doi.org/10.1016/j.atherosclerosis.2017.06.009

has been cited by the following article:

• TITLE: The Impact of PCSK9 on Risk Factors for Ischemic Stroke and Potential Mechanisms

  AUTHORS: Zehua He, Mingtian Lu, Zhejing Ding, Zhengwei Chen, Tianyang Guan, Zhongliang Li, Cheng Zhou, Haiquan Tao, Guangsen Cheng, Yu Liu

  KEYWORDS: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), Ischemic Stroke, Atherosclerosis, Inflammation

  JOURNAL NAME: American Journal of Molecular Biology, Vol.15 No.1, January 24, 2025

  ABSTRACT: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proprotein convertase (PCs) family, which facilitates the degradation of low-density lipoprotein receptors (LDL-R) via intracellular and cell surface pathways, consequently elevating serum LDL-C levels. PCSK9 is implicated in various processes such as lipid metabolism, atherosclerosis, oxidative stress, inflammatory responses, thrombosis, and apoptosis. It is closely linked to ischemic stroke through its role in inducing and advancing atherosclerosis. PCSK9 inhibitors play a useful role in both acute and secondary prevention of ischemic stroke and can reduce the risk of ischemic stroke. This review examines the influence of PCSK9 on the risk factors associated with ischemic stroke and explores its potential mechanisms, and briefly describes the application of PCSK9 inhibitors in ischemic stroke.